3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
10
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
4
Neoplasm Metastasis
4
Breast Neoplasms
4
Neoplasms
3
Urethral Neoplasms
2
Recurrence
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
padeliporfin
4
motexafin gadolinium
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Genetic Testing
2
Carboplatin
2
vinflunine
1
temsirolimus
1
sipuleucel-T
1
niraparib
1
luprolide acetate gel depot
1
apalutamide
1
Tinzaparin
1
Therapeutics
1
Taste
1
Surveys and Questionnaires
1
Specimen Handling
1
Sildenafil Citrate
1
Remote Patient Monitoring
1
Radiation Dose Hypofractionation
1
Pemetrexed
1
Ocoxin
1
Neoadjuvant Therapy
1
Leuprolide
1
Immunotherapy
1
Imatinib Mesylate
1
Imagery, Psychotherapy
1
Genetic Counseling
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urogenital Neoplasms
×
vinflunine
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled